MoonLake Immunotherapeutics
MLTXUnited States
26 filed reports · 368 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
26 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,125 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 1,500 | Dec 2020 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 35 | Dec 2020 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 55 | Sep 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 10, 2026 | 276 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 186 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 658 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 231 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 138 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 135 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 365 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 154 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 120 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 122 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 29, 2024 | 174 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 14, 2023 | 139 | Open |
Financial data
368 concepts · 3,715 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial367 concepts · 3,709 facts · Sep 2020 to Jun 2026
- Supply and manufacturing services39 · Dec 2022 to Jun 2026
- Assets30 · Sep 2020 to Jun 2026
- Liabilities and stockholders equity30 · Sep 2020 to Jun 2026
- Liabilities current30 · Sep 2020 to Jun 2026
- Retained earnings accumulated deficit30 · Sep 2020 to Jun 2026
- Stockholders equity (US GAAP)30 · Sep 2020 to Jun 2026
- Additional paid in capital29 · Sep 2020 to Jun 2026
- Assets current29 · Dec 2020 to Jun 2026
- Liabilities29 · Dec 2020 to Jun 2026
- Prepaid expense current29 · Dec 2020 to Jun 2026
- Cash and cash equivalents at carrying value28 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents28 · Dec 2020 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest28 · Sep 2020 to Dec 2025
- Cash27 · Oct 2020 to Dec 2025
- General and administrative expense (US GAAP)27 · Mar 2021 to Jun 2026
- Increase decrease in prepaid expense27 · Mar 2021 to Jun 2026
- Net cash provided by used in financing activities27 · Mar 2021 to Jun 2026
- Net cash provided by used in operating activities27 · Mar 2021 to Jun 2026
- Net income loss27 · Mar 2021 to Jun 2026
- Net income loss attributable to noncontrolling interest27 · Mar 2021 to Jun 2026
- Operating income loss27 · Mar 2021 to Jun 2026
- Research and development services and license fees27 · Dec 2021 to Mar 2026
- Consultant and other fees26 · Dec 2021 to Jun 2026
- Defined benefit plan interest cost26 · Jun 2021 to Jun 2026
Geography1 concepts · 6 facts · Dec 2024 to Mar 2026
- Number of operating leases6 · Dec 2024 to Mar 2026
Segments
6 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographical2 members · 6 facts
- CH3 · Dec 2024 to Mar 2026
- PT3 · Dec 2024 to Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.